No connection

Search Results

ABBV vs INMD

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
INMD
InMode Ltd.
NEUTRAL
Price
$13.53
Market Cap
$857.2M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
INMD
9.46
Forward P/E
ABBV
15.42
INMD
8.84
P/B Ratio
ABBV
-146.66
INMD
1.25
P/S Ratio
ABBV
6.5
INMD
2.31
EV/EBITDA
ABBV
15.27
INMD
3.6

Profitability

Gross Margin
ABBV
71.46%
INMD
78.53%
Operating Margin
ABBV
35.5%
INMD
25.03%
Profit Margin
ABBV
4.0%
INMD
25.33%
ROE
ABBV
137.96%
INMD
13.53%
ROA
ABBV
9.59%
INMD
6.88%

Growth

Revenue Growth
ABBV
9.1%
INMD
6.1%
Earnings Growth
ABBV
-88.7%
INMD
-63.5%

Financial Health

Debt/Equity
ABBV
--
INMD
0.01
Current Ratio
ABBV
0.72
INMD
9.88
Quick Ratio
ABBV
0.47
INMD
8.55

Dividends

Dividend Yield
ABBV
3.05%
INMD
--
Payout Ratio
ABBV
490.15%
INMD
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
INMD NEUTRAL

InMode presents a classic 'value trap' profile, characterized by a weak Piotroski F-Score of 3/9 and a completely bearish technical trend (0/100). While the company maintains an exceptional balance sheet with virtually no debt (Debt/Equity 0.01) and extreme liquidity (Current Ratio 9.88), these strengths are offset by a severe collapse in earnings growth (-63.50% YoY). The stock trades below its Graham Number ($18.63) but above its growth-based intrinsic value ($10.01), suggesting that while it is cheap on a book-value basis, its growth trajectory is deteriorating.

Strengths
Exceptional gross margins of 78.53%
Virtually debt-free balance sheet (Debt/Equity 0.01)
Extreme short-term liquidity with a Current Ratio of 9.88
Risks
Severe earnings contraction (-63.50% YoY)
Strongly bearish technical momentum (0/100 trend score)
Deteriorating fundamental health as indicated by Piotroski F-Score (3/9)

Compare Another Pair

ABBV vs INMD: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and InMode Ltd. (INMD) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile